Medicare Enrolled

Dr. Arun Nagaraj, MD

Neurology · Dallas, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
Low-engagement
6301 GASTON AVE STE 100W, Dallas, TX 75214
2148273610
In practice since 2011 (14 years)
NPI: 1861786576 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Nagaraj from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Nagaraj? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Nagaraj

Dr. Arun Nagaraj is a neurology specialist in Dallas, TX, with 14 years of NPI registration. Based on federal Medicare data, Dr. Nagaraj performed 8,486 Medicare services across 676 unique beneficiaries.

Between the years covered by Open Payments, Dr. Nagaraj received a total of $6,359 from 47 pharmaceutical and/or device companies across 322 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in neurology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Nagaraj is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 14 years in practice ▲ Top 9% volume in TX $6,359 industry payments

Medicare Practice Summary

Medicare Utilization ↗
8,486
Medicare services
Top 9% in TX for neurology
676
Unique beneficiaries
$10
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~606 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
MRI contrast dye injection (gadoterate)
Administration of gadoterate meglumine, a contrast agent, in a 0.1 ml dose.
7,470 $0 $1
Office visit, established patient (30-39 min)
A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition.
290 $90 $331
Office visit, established patient, complex (40-54 min)
An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter.
141 $127 $440
Methylprednisolone injection, up to 125 mg
An injection of methylprednisolone sodium succinate, a corticosteroid medication, with a dosage of up to 125 mg.
110 $4 $15
New patient office visit (45-59 min)
An initial office visit for a new patient lasting between 45 and 59 minutes. This code covers the total time spent by the physician or qualified healthcare professional on the date of the encounter.
69 $126 $500
Intravenous chemotherapy infusion, 1 hour or less
Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete.
58 $94 $415
Additional sequential IV infusion, 1 hour or less
This code represents an additional intravenous infusion administered sequentially to a primary infusion. It covers the administration time of one hour or less.
55 $22 $95
Office visit, established patient (20-29 min)
An office visit for an existing patient lasting between 20 and 29 minutes. The visit involves medical evaluation and management of the patient's condition.
44 $57 $223
Additional hour of intravenous chemotherapy
This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period.
39 $22 $90
New patient office visit, complex (60-74 min) 38 $154 $630
MRI of brain with and without contrast
An MRI scan of the brain using contrast dye both before and after administration to provide detailed images of brain structures.
37 $136 $1,530
Electromyography of arm or leg muscles
A test that measures the electrical activity in the muscles of the arm or leg using a needle electrode. It helps evaluate the health of muscles and the nerve cells that control them.
30 $78 $100
Limited needle EMG of arm or leg muscles
A test that measures the electrical activity in specific muscles of the arm or leg using a needle electrode. This limited study evaluates muscle function in a targeted area.
25 $50 $65
Diphenhydramine injection, up to 50 mg
An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams.
22 $1 $5
MRI scan of brain, without contrast
A magnetic resonance imaging test of the brain that does not use contrast dye. This procedure creates detailed images of the brain's structure using magnetic fields and radio waves.
20 $82 $1,115
Neurobehavioral status exam, first hour
A clinical assessment of neurobehavioral status lasting one hour. This evaluation examines mental and behavioral functions.
14 $74 $275
MRI of upper spine with and without contrast
An MRI scan of the upper spinal canal performed both before and after the administration of contrast dye to enhance image detail.
13 $169 $1,500
MRI of upper spine without contrast
An MRI scan of the upper spinal canal that does not use contrast dye. This imaging test uses magnetic fields and radio waves to create detailed pictures of the spine.
11 $75 $975
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
1.3% high complexity
91.3% medium
7.4% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$6,359
Total received (2018-2024)
Avg $908/year across 7 years
Top 35% in TX for neurology
47
Companies
322
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$5,921 (93.1%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$266 (4.2%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$173 (2.7%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$715
2023
$1,238
2022
$1,427
2021
$1,383
2020
$539
2019
$569
2018
$489

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Sunovion Pharmaceuticals Inc.
$714
ABBVIE INC.
$666
Novartis Pharmaceuticals Corporation
$507
Biogen, Inc.
$400
Genentech USA, Inc.
$354
EMD Serono, Inc.
$326
Celgene Corporation
$288
UCB, Inc.
$271
Teva Pharmaceuticals USA, Inc.
$260
GENZYME CORPORATION
$257
Merz Pharmaceuticals, LLC
$235
AbbVie Inc.
$198
PFIZER INC.
$196
Nevro Corp.
$153
Allergan Inc.
$152
TG THERAPEUTICS, INC.
$141
Lilly USA, LLC
$109
Janssen Pharmaceuticals, Inc
$108
Horizon Therapeutics plc
$101
Allergan, Inc.
$81
ARGENX US, INC.
$71
Amneal Pharmaceuticals LLC
$68
Amgen Inc.
$66
Alexion Pharmaceuticals, Inc.
$53
Avion Pharmaceuticals
$51
ACADIA Pharmaceuticals Inc
$46
MERZ NORTH AMERICA, INC.
$43
Genentech, Inc.
$40
Octapharma USA, Inc.
$40
SANOFI-AVENTIS U.S. LLC
$39
Alnylam Pharmaceuticals Inc.
$36
Medtronic, Inc.
$34
Banner Life Sciences, LLC
$32
E.R. Squibb & Sons, L.L.C.
$25
Lundbeck LLC
$21
Biohaven Pharmaceutical Holding Company Ltd.
$17
BANNER LIFE SCIENCES, LLC
$17
SK Life Science, Inc.
$17
Assertio Therapeutics, Inc.
$17
Mallinckrodt Enterprises LLC
$17
Grifols USA, LLC
$16
GE HEALTHCARE
$15
Acorda Therapeutics, Inc
$14
CSL Behring
$14
HOSPIRA, INC.
$13
Supernus Pharmaceuticals, Inc.
$13
Sumitomo Pharma America, Inc.
$10
Top 3 companies account for 29.7% of total payments
Associated products mentioned in payments ›
ACTHAR · ADUHELM · AIMOVIG · AJOVY · AMYVID · APTIOM · AUBAGIO · AUSTEDO · BAFIERTAM · BOTOX · BRIUMVI · Briviact · CAMBIA · COPAXONE · CREXONT · DAYBUE · Dhivy · EMGALITY · Enspryng · GILENYA · Gamunex-C · Hizentra · INBRIJA · INTELLIS ADAPTIVESTIM · KESIMPTA · KYNMOBI · LEMTRADA · MAVENCLAD · Mavenclad · NO PRODUCT DISCUSSED · NUPLAZID · NURTEC ODT · Nayzilam · OCREVUS · OCTAGAM IMMUNE GLOBULIN (HUMAN) · ONPATTRO · OXTELLAR XR · PANZYGA · QULIPTA · RYTARY · Rituxan · SOLIRIS · Senza Spinal Cord Stimulation System · TYSABRI · UBRELVY · ULTOMIRIS · UPLIZNA · VYEPTI · VYVGART · XEOMIN · Xeomin · ZEPOSIA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

Most payments (93%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.

Equivalent to $75 per 100 Medicare services performed
Looking for a neurology specialist in Dallas?
Compare neurologists in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse neurologists nearby

Geographic Context

Neurologists within 10 mi
235
Per 100K population
9.0
County median income
$74,149
Nearest hospital
WHITE ROCK MEDICAL CENTER
2.4 mi

Data Sources

Provider Registry NPPES Weekly updates
Medicare Enrollment PECOS Monthly updates
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not public N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Nagaraj is a mixed practice specialist, with above-average Medicare volume (top 9% in TX), with low-engagement industry engagement.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Nagaraj experienced with mri contrast dye injection (gadoterate)?
Based on Medicare claims data, Dr. Nagaraj performed 7,470 mri contrast dye injection (gadoterate) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Nagaraj receive payments from pharmaceutical companies?
Yes. Dr. Nagaraj received a total of $6,359 from 47 companies across 322 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Nagaraj's costs compare to other neurologists in Dallas?
Dr. Nagaraj's average Medicare payment per service is $10. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Nagaraj) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →